March 14-16, 2017 | Boston, MA


About ICI Boston

Thank you to everybody involved in ICI Boston this year. Over three content-packed days, leaders from throughout the field gathered to learn from insightful talks and engage in productive discussions around the key topics driving the industry forward.

Over 27 hours of content were packed into the agenda, and here are a few insights shared that the attendees found most valuable:

  • “Zhen Su’s [Vice President & Global Head, Oncology, EMD Serono] keynote was extraordinarily well done I felt. It was good to get such a thorough overview of the state of immuno-oncology from an industry perspective.”
  • “Kurt Schalper [Assistant Professor of Pathology & Medicine, Yale] provided a very clear and organized overview on checkpoint inhibitors as well as other novel immunotherapy. He also touched upon biomarker aspects of IO therapy, which was very helpful for me to quickly grasp this key aspect of IO field.”
  • “Frederic Triebel [CSO & CMO, Prima Biomed] gave a very interesting talk on LAG3 on T cells and DC activation and Parker Cassidy [CCO, Mitra Biotech] shared great insight into measurements of compound activity within tumor microenvironment.”
  • “It was a great conference, great selection of topics and speakers. I specifically liked the overall possibilities to network.”

This meeting will return next year, so ensure you register your interest to be the first to hear about the development of the meeting.

Hope to see you in 2018!